---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-004458"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:07:41.652387+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports FY2022 net loss $17.6M; cash $22.1M; GT-02287 on track for Phase 1 in H2 2023

## Summary
- Net loss $17.6M ($1.48/share) vs $13.9M ($1.37) in 2021; R&D spend $8.4M, G&A $9.5M.
- Cash and marketable securities $22.1M as of Dec 31, 2022; runway expected into Q2 2024.
- GT-02287 IND-enabling studies completed H1 2023; Phase 1 dossier submission by mid-2023; Australian trial in H2 2023.
- Awarded €1.2M non-dilutive grant for Alpha-1 Antitrypsin Deficiency research program.

## SEC filing metadata
- accession: 0001558370-23-004458
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/0001558370-23-004458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/ganx-20230323x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-004458
- JSON: https://secwatch.observer/filing/0001558370-23-004458.json
- Plain text: https://secwatch.observer/filing/0001558370-23-004458.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $140,108, net income $17.59 million, EPS $1.48.
  - Period: the year ended December 31, 2022
  - Revenue: $140,108
  - Net income: $17.59 million
  - EPS: $1.48
  - Result: reported results
  source text: (audited) ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Revenues: ​ ​ ​ Collaboration revenues ​ $ 132,640 ​ $ 133,928 Other income ​ ​ 7,468 ​ 31,066 Total revenues ​ ​ 140,108 ​ ​ 164,994 ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ Research and development ​ (8,377,290) ​ (7,164,229) General and administrative ​ (9,539,863) ​ (6,826,938) Total operating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837023004458/0001558370-23-004458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.